NO942757D0 - 4-aryl-3-(heteroarylureido)-1,2-dihydro-2-okso-kinolin-derivater - Google Patents

4-aryl-3-(heteroarylureido)-1,2-dihydro-2-okso-kinolin-derivater

Info

Publication number
NO942757D0
NO942757D0 NO942757A NO942757A NO942757D0 NO 942757 D0 NO942757 D0 NO 942757D0 NO 942757 A NO942757 A NO 942757A NO 942757 A NO942757 A NO 942757A NO 942757 D0 NO942757 D0 NO 942757D0
Authority
NO
Norway
Prior art keywords
formula
nitrogen
group
compounds
optionally substituted
Prior art date
Application number
NO942757A
Other languages
English (en)
Norwegian (no)
Other versions
NO942757L (no
Inventor
Ernest S Hamanaka
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO942757L publication Critical patent/NO942757L/no
Publication of NO942757D0 publication Critical patent/NO942757D0/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO942757A 1992-01-23 1994-07-22 4-aryl-3-(heteroarylureido)-1,2-dihydro-2-okso-kinolin-derivater NO942757D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82463992A 1992-01-23 1992-01-23
PCT/US1992/010886 WO1993015058A1 (en) 1992-01-23 1992-12-21 4-aryl-3-(heteroarylureido)-1,2-dihydro-2-oxo-quinoline derivatives as antihypercholesterolemic and antiatherosclerotic agents

Publications (2)

Publication Number Publication Date
NO942757L NO942757L (no) 1994-07-22
NO942757D0 true NO942757D0 (no) 1994-07-22

Family

ID=25241935

Family Applications (1)

Application Number Title Priority Date Filing Date
NO942757A NO942757D0 (no) 1992-01-23 1994-07-22 4-aryl-3-(heteroarylureido)-1,2-dihydro-2-okso-kinolin-derivater

Country Status (16)

Country Link
EP (1) EP0623112B1 (de)
JP (1) JP2668163B2 (de)
KR (1) KR950700284A (de)
AT (1) ATE175196T1 (de)
AU (1) AU3323393A (de)
CA (1) CA2128093C (de)
DE (1) DE69228069T2 (de)
DK (1) DK0623112T3 (de)
ES (1) ES2125325T3 (de)
FI (2) FI930264A (de)
HU (1) HUT63625A (de)
IL (1) IL104420A0 (de)
MX (1) MX9300361A (de)
NO (1) NO942757D0 (de)
WO (1) WO1993015058A1 (de)
ZA (1) ZA93482B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6133326A (en) 1994-08-31 2000-10-17 Pfizer Inc Compositions and methods for decreasing sebum production
US6452008B2 (en) 1998-02-25 2002-09-17 Sumitomo Pharmaceuticals Company, Limited Pyridone derivatives and process for preparing the same
EP1086948A4 (de) * 1998-02-25 2004-03-10 Sumitomo Pharma Pyridonderivate und verfahren zu ihrer herstellung
YU57502A (sh) 2000-02-02 2006-01-16 Warner-Lambert Company Dvojni inhibitori sinteze estara holesterola i estara voska kod poremećaja lojne žlezde
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
FR2874922A1 (fr) * 2004-07-30 2006-03-10 Palumed Sa Molecules hybrides qa ou q est une aminoquinoleine et a est un residu antibiotique, leur synthese et leurs utilisations en tant qu'agent antibacterien
AU2005279050A1 (en) * 2004-07-30 2006-03-09 Centre National De La Recherche Scientifique (Cnrs) Hybrid molecules QA where Q is an aminoquinoline and A is an antibiotic residue, and the synthesis and uses thereof as antibacterial agents
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
CA2592900A1 (en) 2005-01-03 2006-07-13 Myriad Genetics Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE892088L (en) * 1988-07-12 1990-01-12 William Henry Deryk Morris Quinoline derivatives, their production and use
WO1991004027A1 (en) * 1989-09-15 1991-04-04 Pfizer Inc. New n-aryl and n-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme a: cholesterol acyl transferase (acat)
TW205037B (de) * 1989-10-06 1993-05-01 Takeda Pharm Industry Co Ltd
ATE116645T1 (de) * 1990-02-10 1995-01-15 Takeda Chemical Industries Ltd Chromenderivate, deren herstellung und verwendung.
CA2108014A1 (en) * 1991-04-26 1992-10-27 Ernest S. Hamanaka 4-aryl-3-(heteroarylureido)quinoline derivatives

Also Published As

Publication number Publication date
HU9300197D0 (en) 1993-04-28
DE69228069T2 (de) 1999-05-20
FI930264A0 (fi) 1993-01-22
ZA93482B (en) 1994-07-22
MX9300361A (es) 1994-06-30
ES2125325T3 (es) 1999-03-01
CA2128093C (en) 1998-02-03
NO942757L (no) 1994-07-22
ATE175196T1 (de) 1999-01-15
CA2128093A1 (en) 1993-08-05
DK0623112T3 (da) 1999-08-30
EP0623112B1 (de) 1998-12-30
JP2668163B2 (ja) 1997-10-27
FI930264A (fi) 1993-07-24
AU3323393A (en) 1993-09-01
HUT63625A (en) 1993-09-28
EP0623112A1 (de) 1994-11-09
DE69228069D1 (de) 1999-02-11
IL104420A0 (en) 1993-05-13
FI20010074A (fi) 2001-01-12
WO1993015058A1 (en) 1993-08-05
KR950700284A (ko) 1995-01-16
JPH07503712A (ja) 1995-04-20

Similar Documents

Publication Publication Date Title
DK1026147T3 (da) Forbindelser, der er anvendelige som mellemprodukter i fremstillingen af piperidinderivater
NO20013379L (no) 4-okso-1,4-dihydro-3-kinolinkarboksamider som antivirusmidler
FI943561A (fi) Uudet ainekoostumukset
DK254587D0 (da) Positionsspecifikke alkyleringsmidler
DE69428142D1 (de) Quinolin- oder Quinazolinderivate, deren Herstellung und Verwendung
NO942757D0 (no) 4-aryl-3-(heteroarylureido)-1,2-dihydro-2-okso-kinolin-derivater
DE69314929D1 (de) Benzolderivate
ES2077697T3 (es) Derivados de 1-fenoxicarbonil-2-pirrolidinona y agentes nootropicos.
YU90192A (sh) LANOSTA-7,9-DIEN-3β, 32-DIOL I POSTUPAK ZA NJEGOVO DOBIJANJE,9-DIEN-3BETA, 32-DIOL I POSTUPAK ZA NJEGOVU SINTEZU